William Blair Investment Banking

William Blair acted as the exclusive financial advisor to Plasticade - American Louver Company in connection with its sale to Radial Equity Partners. Learn more: https://lnkd.in/gJxZeXxU

William Blair acted as financial advisor to H.I.G. Capital in connection with its acquisition of SkinCure Oncology. Learn more: https://lnkd.in/edyckrgx

William Blair advised on 20 transactions in September with an aggregate value of approximately $7.5 billion. Select transactions are listed below:

Our Frankfurt office recently had the pleasure of hosting students from the SCOPE Maastricht. Attendees met with our bankers, learned about our early career programme, heard details about the recruitment process, and gained real-life insight into what they can expect from a career in investment banking through a detailed case study. We look forward to continuing to host events that support students and provide valuable insights into careers in financial services. #WorkatWilliamBlair

Improving LP-led pricing, continuing adoption by both GPs and LPs, and a growing supply of capital has the secondary market poised for a full rebound—and possibly record volumes—by year-end. Indeed, bullish early-year predictions for both LP- and GP-led activity appear to be playing out, with especially high GP-led deal activity paced by strong interest in multi-asset continuation funds. William Blair’s Private Capital Advisory team outlines the state of the secondary market in its latest report. Read the full report: https://lnkd.in/gA99nenP

William Blair recently announced the addition of Connor O’Keeffe as a managing director in the firm’s growing Private Capital Advisory team. Based in London, O’Keeffe will focus on fund placement and advisory services for general partners (GPs) throughout Europe. O’Keeffe is also the latest addition to William Blair’s holistic platform for financial sponsors in Europe. Previously he was a senior member of the Credit Suisse Private Funds Group for more than 16 years, focusing on private placements and related services, including fund placement, direct corporate capital raising (directs and co-investments), and GP-led secondaries across Europe and Asia. Learn more: https://lnkd.in/g_AJFBhW

William Blair acted as exclusive financial advisor to Homrich Berg and New Mountain Capital in connection with the company’s pending minority investment from TPG Growth. Learn more: https://lnkd.in/gKgsFJjR

There’s less than a week left to apply for our 2025 London Summer Analyst Programme! Submit your application by October 10 and take the first step toward your dream career: https://lnkd.in/eVZqwyJ2

William Blair acted as exclusive financial advisor and placement agent to Cogenuity Partners, LLC in connection with its oversubscribed co-investment capital raise for United Safety & Survivability Corporation. Learn more: https://lnkd.in/gJUkz_jg

Biopharma got a much-needed shot in the arm in the third quarter by way of the Federal Reserve’s September rate cut, and major indices bounced back from this summer’s broader volatility, ending the quarter near multi-year highs. Meanwhile, the IPO window reopened after Labor Day, overall secondary activity surpassed 2023 totals, and the private financing market is on track to exceed last year. But third-quarter dealmaking was anemic with only one public M&A transaction announced valued at more than $1 billion. All eyes now turn to the U.S. presidential election, and the Federal Reserve’s ongoing easing cycle, as the biopharma sector sets itself up for a broader recovery in 2025. William Blair's biopharma team shares additional perspectives on the biopharma environment and what to expect heading into 2025: https://lnkd.in/gdzbrUnr